Cargando…

NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection

Background: Pulmonary affection (PA) is associated with a substantial increase in morbidity and mortality in patients with idiopathic inflammatory myopathies (IIM). However, the underlying immune mechanisms of PA remain enigmatic and prompt deeper immunological analyses. Importantly, the Janus-faced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawlitzki, Marc, Nelke, Christopher, Rolfes, Leoni, Hasseli, Rebecca, Tomaras, Stylianos, Feist, Eugen, Schänzer, Anne, Räuber, Saskia, Regner, Liesa, Preuße, Corinna, Allenbach, Yves, Benveniste, Olivier, Wiendl, Heinz, Stenzel, Werner, Meuth, Sven G., Ruck, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534165/ https://www.ncbi.nlm.nih.gov/pubmed/34685530 http://dx.doi.org/10.3390/cells10102551

Ejemplares similares

High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies
por: Nelke, Christopher, et al.
Publicado: (2022)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis
por: Preuße, Corinna, et al.
Publicado: (2022)

Sequestosome‐1 (p62) expression reveals chaperone‐assisted selective autophagy in immune‐mediated necrotizing myopathies
por: Fischer, Norina, et al.
Publicado: (2019)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
por: Pawlitzki, Marc, et al.
Publicado: (2022)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Inclusion body myositis and associated diseases: an argument for shared immune pathologies
por: Nelke, Christopher, et al.
Publicado: (2022)

Clinical Course, Myopathology and Challenge of Therapeutic Intervention in Pediatric Patients with Autoimmune-Mediated Necrotizing Myopathy
por: Della Marina, Adela, et al.
Publicado: (2021)

Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis
por: Nelke, Christopher, et al.
Publicado: (2023)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited
por: Knauss, Samuel, et al.
Publicado: (2019)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients
por: Schänzer, Anne, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Endoplasmic reticulum‐stress and unfolded protein response‐activation in immune‐mediated necrotizing myopathy
por: Preusse, Corinna, et al.
Publicado: (2022)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

NanoString technology distinguishes anti‐TIF‐1γ(+) from anti‐Mi‐2(+) dermatomyositis patients
por: Preusse, Corinna, et al.
Publicado: (2021)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

The NKG2D – IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies
por: Ruck, Tobias, et al.
Publicado: (2015)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Curcumin: Useful add-on for Rheumatic Diseases?
por: Tomaras, Stylianos, et al.
Publicado: (2022)

MRI and muscle imaging for idiopathic inflammatory myopathies
por: Malartre, Samuel, et al.
Publicado: (2021)

Bilateral vocal cord palsy as complication of CNS tuberculosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2023)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Biomarkers in Inflammatory Myopathies—An Expanded Definition
por: Benveniste, Olivier, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review
por: Kedor, Claudia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6r0e59i317jg62l8ncealtjqop